SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Omeros -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (417)7/2/2017 11:21:45 PM
From: Howard Williams  Respond to of 464
 
>>Did not short seller Doyle claim that the company does not have any Ph3 trial ongoing with OMS 721?<<

Yes "Doyle" did Jim.

And note the Phase 3 study start date was February 23, 2017.



To: Biotech Jim who wrote (417)7/2/2017 11:40:29 PM
From: BulbaMan  Respond to of 464
 
Thanks BJ! Good catch.
Peace & good health,
Bulba



To: Biotech Jim who wrote (417)7/2/2017 11:58:37 PM
From: BulbaMan  Read Replies (1) | Respond to of 464
 
Also just posted on clinicaltrials.gov re Omeros Phase 2 trial of OMS721 for IgA Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and C3 Glomerulopathy (C3G)
clinicaltrials.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News